Onco Clinic Consult S.A. — Clinical Trial Site

22 Registered trials

8 Currently recruiting

Organisation

Onco Clinic Consult S.A.

Location

Craiova, Romania

Identifier

ORG-100033776

Address

Strada Sararilor 28j, 200508, Romania

Departments

#3207:Oncology
040009: Ambulatory
3207: Oncology
Departamentul de Oncologie Medicala
Medical Oncology
Medical Oncology, 28J Sărarilor Street, 200516, Craiova Municipality, Dolj County
Oncologie
Oncologie Medicală
Oncology
Specialized Ambulatory, 28J Sărarilor Street, Craiova Municipality, Dolj County

Clinical trials at this site (22)

Search interface

Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study Recruiting

2025-523803-31-00 Advanced non-small cell lung cancer (NSCLC) 4 2026-04-16
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting

2023-503708-10-00 Locally advanced or metastatic breast cancer 5 2024-02-20
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
Pan tumor Roll Over Study Recruiting

2023-506914-32-00 Pan tumor 4 2020-05-05
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
A study to learn if a combination of Fianlimab and Cemiplimab versus Cemiplimab alone is more effective for adult participants with Advanced… Ended

2022-501483-18-00 Advanced Non-Small Cell Lung Cancer 10 2025-03-28
A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab tr… Ended

2024-513160-25-00 Melanoma and Non-small-cell lung cancer 5 2024-10-30
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam… Ended

2023-507448-36-00 Non-small Cell Lung Cancer 5 2024-02-16
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Neoplasms, Head and Neck 4 2024-01-19
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St… Ended

2023-508372-10-00 Non small Cell Lung cancer 4 2021-05-19
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastati… Ended

2023-506882-70-00 Non-small-cell lung cancer 5 2024-08-16
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21